NCT06895031
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Recruiting · Phase 2 · Guangzhou JOYO Pharma Co., Ltd · registry updated 2026-03-06
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.
Inclusion
- Histologically or pathologically confirmed solid tumors with RAS mutation via molecular tests.
- Patients with RAS mutation who have disease progression or intolerance after adequate standard treatment
- Eastern Cooperative Oncology Group (ECOG) performance status in 0 or 1
- Adequate organ function
Exclusion
- Presence of central nervous system (CNS) metastases; however, subjects with previously treated brain metastases may be enrolled if clinically stable.
- Gastrointestinal (GI) disorders that may interfere with drug administration/absorption, including but not limited to: Dysphagia or inability to swallow tablets， Malabsorption syndrome，Refractory nausea, vomiting, or diarrhea，Chronic GI diseases (e.g., Crohn's disease, ulcerative colitis)
- Congestive heart failure with New York Heart Association (NYHA) functional class ≥II or left ventricular ejection fraction (LVEF) \<50%.
- Any other condition deemed by the investigator to potentially compromise study outcomes or lead to premature termination, including but not limited to: Alcohol or substance abuse，Concurrent severe medical conditions (e.g., psychiatric disorders requiring active treatment)， Familial or social circumstances that may affect patient safety, compliance, or study data collection.